9 results about "Hippocampal region" patented technology

The application discloses a new use of Leonurine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating radiation-induced brain injury, specifically, providing a safe and effective therapeutic drug for iron death, neuroinflammation, neuron damage and lipid metabolism disorder accompanying the radiation-induced brain injury, solving the technical problem of lack of specific treatment means in the prior art, and having a wide clinical application prospect. Experiments adopt a C57BL / c mouse 30 Gy whole brain X-ray radiation model, and results show that Leonurine can significantly improve the body weight decrease and survival rate of the model mice, reduce the serum IL-6 and IFN-alpha levels, inhibit the activation of microglial cells in the cerebral cortex and hippocampus, protect and repair damaged neurons, and improve the ultrastructure of mitochondria and synapses; meanwhile, the expression of GPX4 and SLC7A11 proteins in the brain tissue is up-regulated, the GSH content is increased to inhibit iron death, and the levels of GPE, GPS and GPC related to lipid metabolism are restored.

The present invention provides a basis for using soluble fiber, particularly compositions comprising Agave fructans, to prevent or treat the accumulation of lipids, particularly ceramides in the liver and brain and lipofuscin in the liver, improving the overall integrity of both organs, with treatment being feasible to prevent fatty liver disease and also prevent Alzheimer's disease (AD). In the present invention, we analyze alterations in lipid metabolism in the liver and ceramide production in the brain of transgenic mice (APP / PS1, TG) for AD. Our results indicate that microvesicular lipid accumulation within hepatocytes is increased in TG mice compared to the control group. Furthermore, in the brains of TG mice, a greater accumulation of ceramides is observed in the somatosensory cortex and entorhinal cortex; in the CA1 region of the hippocampus and in the motor cortex, no significant increase was observed when compared to the control group.

The application provides a robot positioning mapping method based on a visual cortex and hippocampus space coding, and the method comprises the following steps: acquiring linear velocity and angular velocity through a wheel encoder and an inertial measurement unit, and obtaining robot pose information through path integration; collecting scene images by using a camera and extracting GIST features, obtaining a winning cell in a view cell network through Euclidean distance matching, updating weights, and introducing a posteriori entropy adaptive threshold to perform robust scene matching; storing the pose information and the successfully matched weight vector into a hippocampus CA1 area location cell, eliminating cumulative errors through iterative optimization, controlling the map size through space density redundancy pruning, and adopting a hierarchical switching strategy to perform scale stretching optimization, so that fast mapping is realized. Through simulating a biological space coding mechanism, the application improves scene recognition robustness, positioning consistency and mapping efficiency, and is suitable for intelligent navigation of a mobile robot.

The present disclosure relates to the field of biomedicine, and discloses a nutritional composition for intervention or treatment of autism and a preparation method thereof, aiming to solve the problems of safety, compliance and insufficient targeting mechanism of existing intervention programs for social impairment of autism. The composition comprises leucine, isoleucine and valine in a molar ratio of 1:1:1, with a total concentration of 0.753 mg / kg of body weight, in the form of oral liquid, and a pH of 6.87.4. The preparation method comprises weighing the amino acids according to the molar ratio, dissolving them in 0.9% sodium chloride injection, filtering, dispensing and sealing. The present application can safely and effectively improve the social impairment of autism patients and plays a role by up-regulating the expression of MyT1L in the hippocampus.

The present application relates to a pharmaceutical composition for treating chronic pain and pain-related memory impairment diseases, and belongs to the technical field of biological medicine. Through animal experiments, it is confirmed that the expression of C3 in the hippocampal area of chronic pain mice is increased, and exogenous C3 injection can induce pain and memory impairment phenotype. The present application proposes to use C3-C3aR inhibitors, such as small molecule inhibitor SB290157, to block the pathway. The pharmaceutical composition can be administered by systemic injection or targeted brain region administration to achieve intervention. C3aR inhibitors can simultaneously improve pain behavior and memory function in SNI model mice. By regulating the C3-C3aR signaling pathway in the hippocampal area, the present application directly acts on the pathological core link of pain-memory comorbidity, and provides a small molecule targeted treatment path for chronic pain patients.

The application relates to a system and method for treating Alzheimer's disease, and belongs to the field of medical devices. The system comprises a multi-modal data acquisition module, an individualized simulation navigation module, a precise signal generation and driving module, and a closed-loop feedback control module. The system constructs an individual head model through finite element analysis to optimize electrode distribution, generates an interference envelope in the hippocampus area by using two high-frequency currents, and realizes closed-loop adjustment of parameters by combining a repeated continuous mode and physiological feedback. The application realizes non-invasive and accurate regulation of a deep target point, significantly improves hippocampal oscillation synchronization and synaptic plasticity, improves the memory of patients, reduces the activation of the surface cortex, and has good clinical safety.

The application discloses an olfactory training system for activating a motor-olfactory-hippocampal neural network and application, the system comprises a plurality of different odor sources, the odor source is used for alternating olfactory stimulation to stroke patients, so as to improve the cognitive function and / or olfactory function of the patient. The application firstly discloses that the function connection of the motor-olfactory-cognitive brain area is disordered after stroke, the function of the VIP neuron of the motor cortex (MO) around the infarction is inhibited; the VIP neuron of the MO region dominates the GABA neuron of the dorsal peripeduncular area (DP) through an inhibitory pathway, activating the pathway can remove the inhibition of the glutamatergic pyramidal neuron of the DP, enhance the excitatory input to the hippocampal CA3 region, and restore the olfaction and spatial memory. The application proves that the structured olfactory training can activate the loop, and significantly improve the cognitive function of the stroke patient. The application provides a simple and non-invasive stroke rehabilitation strategy.

This invention discloses an implantable medical device comprising a polyethylene glycol diacrylate hydrogel matrix and monodisperse guanine peptide nucleic acid self-assembled microspheres immobilized within the polyethylene glycol diacrylate hydrogel matrix. The guanine peptide nucleic acid self-assembled microspheres exhibit a spatial quasi-periodic distribution within the hydrogel matrix characterized by short-range order and long-range disorder. This implantable medical device combines the light-harvesting advantages of biomimetic structures, the wide bandgap photoelectric properties of bio-organic semiconductors, and the flexible tissue integration capabilities of hydrogels to obtain an amorphous photonic crystal material with programmable optical properties and wide bandgap semiconductor properties. This product aims to achieve efficient, stable, and biosafe neurophotomodulation and, through mechanisms such as enhancing cortical gamma oscillations, effectively activating disease-related microglia in the hippocampus, and promoting the clearance of β-amyloid plaques, provides a novel, non-genetic, implantable optical therapy strategy for neurodegenerative diseases.

The application discloses a method for constructing a microwave radiation animal brain injury model based on a medial septum-hippocampus CA3 cholinergic nerve loop regulation, comprising the following steps: setting electromagnetic radiation conditions, and performing electromagnetic radiation treatment on test animals; comparing whether a cholinergic nerve loop between the medial septum and the hippocampus CA3 is activated before and after the electromagnetic radiation treatment; and if the cholinergic nerve loop is activated, constructing an electromagnetic radiation animal brain injury model by using the electromagnetic radiation conditions. The application can accurately construct the electromagnetic radiation animal brain injury model, and increases the possibility of elucidating the molecular mechanism of the electromagnetic radiation brain injury effect and the research and development of prevention and treatment drugs.